LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Elenco Azioni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

168.84 0.43

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

162.75

Massimo

171

Metriche Chiave
By Trading Economics
Entrata	262M -15M
Vendite	1.6M 996M
EPS	2.06
Margine di Profitto	-1.486
Dipendenti	18,300
EBITDA	-11M 187M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+20.12% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-388M 8.1B
Apertura precedente	168.41
Chiusura precedente	168.84

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

117.16 / 144.77 Supporto e resistenza

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2026, 22:50 UTC

Utili

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mag 2026, 22:49 UTC

Utili

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mag 2026, 22:32 UTC

Utili

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mag 2026, 22:57 UTC

Discorsi di Mercato

Utili

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mag 2026, 22:26 UTC

Utili

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mag 2026, 22:24 UTC

Utili

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mag 2026, 22:19 UTC

Utili

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mag 2026, 22:13 UTC

Utili

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mag 2026, 22:11 UTC

Utili

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mag 2026, 22:11 UTC

Utili

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mag 2026, 22:10 UTC

Utili

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mag 2026, 22:08 UTC

Utili

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mag 2026, 22:07 UTC

Utili

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mag 2026, 22:05 UTC

Utili

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

20.12% in crescita

Previsioni per 12 mesi

Media 202.35 USD 20.12%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

Recent bullish events outweigh bearish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.